EXACT Sciences Corporation (NASDAQ:EXAS) reported a rise of 3.1% or 626,444 shares in its short interest. The short figure came in at 21.9% of the total floats. The average daily volume of 6,888,390 shares suggests that the days to cover 20,950,888 short positions, as on June 15,2016, will be 3. On May 31,2016, the short interest was 20,324,444 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.
EXACT Sciences Corporation (NASDAQ:EXAS): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $10.54 and $10.46 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $11.64. The buying momentum continued till the end and the stock did not give up its gains. It closed at $11.54, notching a gain of 4.06% for the day. The total traded volume was 7,038,711 . The stock had closed at $11.09 on the previous day.
The company shares have dropped -60.15% from its 1 Year high price. On Jun 29, 2015, the shares registered one year high at $30.30 and the one year low was seen on Mar 1, 2016. The 50-Day Moving Average price is $7.36 and the 200 Day Moving Average price is recorded at $7.09.
EXACT Sciences Corporation (NASDAQ:EXAS) has climbed 5.2% in the past week and advanced 77.54% in the last 4 weeks. In the past week, the company has outperformed the S&P 500 by 6.94% and the outperformance has advanced to 82.91% for the last 4 weeks period.
Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The Company has developed a non?invasive screening test called Cologuard for colorectal cancer. Its Cologuard test is a non?invasive stool?based deoxyribonucleic acid (DNA) (sDNA) screening test designed to detect DNA markers. In addition to DNA markers, its test includes a protein marker to detect blood in the stool, utilizing an antibody?based fecal immunochemical test (FIT). The Companys Cologuard test is designed to detect pre?cancerous lesions or polyps, and each of the four stages of colorectal cancer. By detecting pre?cancers and cancers early with its test, affected patients can be referred to colonoscopy, during which the polyps or lesions can be removed. The companys test also detects blood in stool, utilizing an antibody based FIT test.